By Editor , 12 September 2026 Ascletis Launches U.S. Phase I Trial for Oral Obesity Drug ASC36 Hong Kong – September 11, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) has initiated a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist for obesity, after securing Investigational New Drug clearance from the FDA.
